Yet another weight loss drug fizzles

first_img STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. GET STARTED By Meghana Keshavan Jan. 4, 2017 Reprints What is it? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Meghana Keshavan Biotech Correspondent Meghana covers biotech and contributes to The Readout newsletter. When it comes to weight loss, Arena Pharmaceuticals is throwing in the towel.The small San Diego biotech company had once expected its anti-obesity drug, Belviq, to be a blockbuster — after all, more than one-third of Americans are obese. But the market wasn’t interested, and sales never lived up to expectations — leading the company to slash its employee count by 120, nearly three-quarters of its workforce. Biotech Kristoffer Tripplaar/Sipa/AP center_img What’s included? Log In | Learn More About the Author Reprints Yet another weight loss drug fizzles Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED [email protected] @megkesh Tags pharmaceuticalsSTAT+last_img read more